POLE and malignant colon neoplasm: POLEM is distinct from ATOMIC in that it also includes POLE mutant colon cancers and has been designed to incorporate the recent IDEA collaboration trial data comparing 3 months vs 6 months fluoropyrimidine-based chemotherapy.25 The study opened in August 2018 and will be conducted in over at least 30 UK sites with potential for international collaboration.